ROQUEFORT THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.25 GBX | 0.00% |
|
+17.98% | -27.59% |
| May. 23 | Windward wins deal; Kodal progresses at Bougouni | AN |
| May. 23 | Roquefort Therapeutics plc Announces Executive and Board Changes | CI |
| Sales 2022 | - | Sales 2023 | 200K 255K | Capitalization | 9.36M 11.95M |
|---|---|---|---|---|---|
| Net income 2022 | -1M -1.28M | Net income 2023 | -1M -1.28M | EV / Sales 2022 | - |
| Net cash position 2022 | 2.32M 2.96M | Net cash position 2023 | 537K 686K | EV / Sales 2023 | 44.1 x |
| P/E ratio 2022 |
-4.24
x | P/E ratio 2023 |
-5.37
x | Employees | 10 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 39.6% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | +17.98% | ||
| Current month | +19.32% | ||
| 1 month | +15.38% | ||
| 3 months | -43.24% | ||
| 6 months | -19.23% | ||
| Current year | -27.59% |
1 week
4.45
6.02
1 month
4.006.02
Current year
3.859.50
1 year
3.859.50
3 years
3.8513.63
5 years
3.8513.63
10 years
3.8513.63
| Managers | Title | Age | Since |
|---|---|---|---|
Ajan Reginald
CEO | Chief Executive Officer | 52 | 22-09-15 |
| Chairman | 51 | 20-08-16 | |
Armand Keating
CTO | Chief Tech/Sci/R&D Officer | - | 22-09-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jean Duvall
BRD | Director/Board Member | 63 | 22-04-04 |
Darrin Disley
BRD | Director/Board Member | 57 | 22-09-15 |
| Chairman | 51 | 20-08-16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 5.25 | 0.00% | 59 837 |
| 24-05-24 | 5.25 | -4.55% | 73,559 |
| 24-05-23 | 5.5 | +23.60% | 2,548,240 |
| 24-05-22 | 4.45 | 0.00% | 0 |
| 24-05-21 | 4.45 | 0.00% | 22,276 |
Delayed Quote London S.E., May 28, 2024 at 11:35 am EDT
More quotes
Roquefort Therapeutics PLC is a biotechnology company. The Company is focused on developing pre-clinical medicines focused on treating hard-to-treat cancers. The Companyâs portfolio consists of five fully funded, patent-protected pre-clinical anti-cancer medicines. Its portfolio of medicines includes Midkine antibodies with in vivo efficacy and toxicology studies; Midkine oligonucleotide therapeutics with anti-cancer gene editing action; Midkine mRNA therapeutics targeting solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with in vivo efficacy, and MK cell therapy with direct and NK-mediated anti-cancer action. The Company operates through its subsidiaries Lyramid Pty Ltd (Lyramid) and Oncogeni Ltd. Lyramid is engaged in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression). Oncogeni Ltd has developed two families of cell and RNA oncology medicines.
Calendar
2024-10-24
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -27.59% | 8.66M | |
| -4.98% | 116B | |
| +8.47% | 99.76B | |
| +11.82% | 68.91B | |
| +23.96% | 65.73B | |
| +11.89% | 44.19B | |
| +14.52% | 43.8B | |
| +20.69% | 36.34B | |
| +8.02% | 26.39B | |
| -4.58% | 22.71B |
- Stock Market
- Equities
- ROQ Stock
